TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28715503
Drug: Aspirin discontinuation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin discontinuation (4 days before the operative day)
Study: 26168823
Drug: Low-dose sevoflurane
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sevoflurane (0.8% end-tidal) with propofol (Group B)
Study: 15067027
Drug: S plus
Normalized name: BSS Plus
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S plus CT (Surgery plus Chemotherapy)
Study: 15067027
Drug: S plus
Normalized name: BSS Plus
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S plus RT plus CT (Surgery plus Radiotherapy plus Chemotherapy)
Study: 9304439
Drug: 0.25% WP-934
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% WP-934 ophthalmic solution
Study: 9304439
Drug: 0.5% WP-934
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% WP-934 ophthalmic solution
Study: 7686715
Drug: Intravenous piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous piperacillin (PIPC) 2 g once after surgery, and twice on the following day (Group A)
Study: 7686715
Drug: Intravenous piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous piperacillin (PIPC) followed by oral tosufloxacin tosilate (TFLX) 300 mg twice daily from the second to the fifth day (Group B)
Study: 20863932
Drug: Subcutaneous Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Tramadol (1.5 mg.kg⁻¹)
Study: 20863932
Drug: Intravenous Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Tramadol (1.5 mg.kg⁻¹)
Study: 12552190
Drug: Aprotinin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (n = 23), bolus of 2 x 10(6) kallikrein inactivator units (KIU), followed by an infusion of 5 x 10(5) KIU/h
Study: 12552190
Drug: Epsilon amino‐caproic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epsilon amino‐caproic acid (EACA) (n = 22), bolus of 150 mg/kg, followed by a 15 mg/kg/h infusion
Study: 8696647
Drug: Self-donated blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-donated blood for pleurodesis (50 ml instillations, 120 ml for 1 patient)
Study: 1802958
Drug: Plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived hepatitis B vaccine (HB Vax, MSD)
Study: 1802958
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (Engerix B, SK&F)
Study: 25261340
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (blue-colored hand disinfectant)
Study: 22103778
Drug: COXIB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: COXIB group (n = 30) received either 40 mg parecoxib iv or 120 mg etoricoxib orally 1 h before surgery.
Study: 22103778
Drug: STEROID group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEROID group (n = 30) received 8 mg dexamethasone iv.
Study: 22103778
Drug: Group COMBI
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group COMBI (n = 29) received both COX-2 inhibitor and dexamethasone.
Study: 17634165
Drug: Licorice flavonoid
Normalized name: Licorice Flavanoid Oil
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice flavonoid oil (LFO) at doses of 300 mg, 600 mg, and 1200 mg per day
Study: 2694857
Drug: Oral Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Midazolam (0.3 mg/kg bw)
Study: 2694857
Drug: Rectal Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal Midazolam (0.5 mg/kg bw)
Study: 7373
Drug: Metoprolol 25
Normalized name: metoprolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 25 mg three times daily for 1 week, then 100 mg three times daily for 5 weeks
Study: 31568009
Drug: 20mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg of methylprednisolone twice daily for 5 days
Study: 15001641
Drug: Urocortin-1 infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urocortin-1 infusion (50 micro g iv over 1 h)
Study: 7523776
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg orally daily
Study: 3232776
Drug: Thiopentone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (5 mg/kg) followed by suxamethonium (1.5 mg/kg)
Study: 3232776
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg/kg) followed by thiopentone (5 mg/kg)
Study: 24308798
Drug: Weekly peer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly peer-based social skills training
Study: 18812476
Drug: Albiglutide 32
Normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albiglutide 32 mg
Study: 18812476
Drug: Albiglutide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide (16 or 64 mg)
Study: 8255512
Drug: Benazepril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (20 mg o.d.)
Study: 8255512
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg o.d.) and Chlorthalidone (25 mg o.d.)
Study: 24652467
Drug: Rituximab therapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab therapy (500 mg or 1000 mg infusions on study days 1 and 15)
Study: 24652467
Drug: Rituximab therapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab therapy with oral corticosteroids during infusion
Study: 23566945
Drug: MenACWY-CRM197 (correlation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM197 (correlation with antibody persistence)
Study: 18197842
Drug: Early loaded
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loaded dental implants (n=16)
Study: 18197842
Drug: Delayed loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loaded dental implants (n=14)
Study: 18197842
Drug: All dental
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dental implants
Study: 10029963
Drug: Triazolam 0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.005 mg/kg
Study: 10029963
Drug: Triazolam 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.015 mg/kg
Study: 10029963
Drug: Triazolam 0.030
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.030 mg/kg
Study: 7728861
Drug: Restarting heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restarting heparin postsheath removal
Study: 7728861
Drug: Preprocedure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprocedure treatment with corticosteroids
Study: 2137218
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg/day (group 1, n = 68)
Study: 2137218
Drug: Nifedipine 40
Normalized name: nifedipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 40 mg/day (group II, n = 68)
Study: 30637626
Drug: GSK2798745 (TRPV4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2798745 (TRPV4 channel blocker)
Study: 30637626
Drug: GSK2798745 (TRPV4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2798745 (TRPV4 channel blocker) with high-fat meal
Study: 22971278
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil combined with Anluohuaxian capsule for 48 weeks
Study: 11908355
Drug: Nondesensitizing dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nondesensitizing dentifrice containing 0.243% sodium fluoride in a silica base (Colgate Winterfresh Gel)
Study: 8821519
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of diclofenac and codeine phosphate (50 mg each)
Study: 8821519
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of diclofenac and codeine phosphate (50 mg each)
Study: 8821519
Drug: Suppositories (rectal)
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppositories (rectal)
Study: 3936198
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus probenecid
Study: 28778455
Drug: rush oral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rush oral immunotherapy (rOIT) for 3 months
Study: 28778455
Drug: rush oral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rush oral immunotherapy (rOIT) for 12 months
Study: 25533009
Drug: Oral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-carnitine (20 mg/kg/day) for 12 months
Study: 22757655
Drug: 1,800 mg
Normalized name: daratumumab-hyaluronidase-fihj 1,800 mg-30,000 unit/15 mL SUBCUT VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,800 mg G-GR
Study: 21076630
Drug: Aggressive lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lipid targets (LDL-C ≤ 70 mg/dL, non-HDL-C ≤ 100 mg/dL)
Study: 21076630
Drug: Standard lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lipid targets (LDL-C ≤ 100 mg/dL, non-HDL-C ≤ 130 mg/dL)
Study: 15721120
Drug: Ethanol dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol dose of 1 to 2 ml
Study: 15721120
Drug: Ethanol dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol dose of >2 ml
Study: 12642173
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 mg intravenously)
Study: 29506566
Drug: Laparoscopic inguinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic inguinal ligament suspension (LILS)
Study: 26986459
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC 5) followed by external radiotherapy (60 Gy/30 fractions/6 weeks)
Study: 26986459
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC 5) followed by accelerated hypofractionated radiotherapy (AHFx‐RT) (48 Gy/20 fractions/4 weeks) with concomitant chemotherapy (cisplatin 30 mg/m² weekly)
Study: 22510183
Drug: SABER‐Bupivacaine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABER‐Bupivacaine 5.0 mL (660 mg)
Study: 20448126
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg (ATOR40)
Study: 20448126
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg (ATOR10)
Study: 12805079
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose ADMA
Study: 10536648
Drug: Chronic running
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic running + Hormone Replacement Therapy (HRT)
Study: 6120945
Drug: Beta-blocker (metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (metoprolol or oxprenolol)
Study: 28007924
Drug: Intravaginal metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal metronidazole 750 mg plus miconazole 200 mg for 5 consecutive nights each month for 12 months
Study: 25965846
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment group (ITG) received 325 mg/day of ferrous sulphate daily.
Study: 25965846
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment group (ITG)
Study: 15741988
Drug: Two portions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two portions of fruits and vegetables (2 FV) daily for 14 days
Study: 15741988
Drug: Five portions
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five portions of fruits and vegetables (5 FV) daily for 14 days
Study: 9468162
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (4 microg/kg/min)
Study: 8562146
Drug: Tomudex 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomudex 3.0 mg/m2 given once every 3 weeks
Study: 8562146
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2 for 5 days (the Mayo regimen), given every 4‐5 weeks
Study: 2698941
Drug: Cromakalim 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromakalim 1.5 mg
Study: 1152354
Drug: Digitoxin tablets
Normalized name: Digitoxin Tablets
DrugBank: Digitoxin (DB01396)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digitoxin tablets
Study: 1152354
Drug: Digitoxin elixir
Normalized name: Digitoxin
DrugBank: Digitoxin (DB01396)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digitoxin elixir
Study: 25630040
Drug: KD-247 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: KD-247 (all doses)
Study: 23510091
Drug: L‐NMMA (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (8 mg kg(‐1) h(‐1))
Study: 21525253
Drug: High-MUFA ground
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-MUFA ground beef (3.21 g more 18:1(n-9), 1.26 g less 18:0, 0.89 g less 16:0, and 0.36 g less 18:1(trans) fatty acids per patty)
Study: 19625785
Drug: rTMS (18,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS (18,000 pulses over 3 weeks) + Citalopram (20 mg/day for 9 weeks)
Study: 19625785
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment + Citalopram (20 mg/day for 9 weeks)
Study: 6606942
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of glucagon
Study: 16699970
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of scopolamine butylbromide
Study: 15056110
Drug: Light orthodontic
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light orthodontic forces (25 g)
Study: 15056110
Drug: Heavy orthodontic
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy orthodontic forces (225 g)
Study: 11806864
Drug: High-dose glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose glycine treatment
Study: 11806864
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (clozapine or olanzapine)
Study: 9742977
Drug: Intensive blood-glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood-glucose control with metformin (n=342)
Study: 9742977
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of metformin in sulphonylurea-treated patients (n=268)
Study: 9742977
Drug: Combined analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined analysis of metformin-allocated patients
Study: 2929979
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sublingual nifedipine after weaning from bypass
Study: 27965306
Drug: Intralesional (IL)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional (IL) injection
Study: 27965306
Drug: Intranodal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranodal (IN) injection
Study: 27965306
Drug: Both intralesional
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intralesional and intranodal (ILN) injection
Study: 16418872
Drug: Rowatinex 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rowatinex 200 mg t.i.d.
Study: 12945875
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enoxaparin once daily
Study: 10580782
Drug: Current users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current users of lipid-lowering medications
Study: 10580782
Drug: Past users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past users of lipid-lowering medications
Study: 10580782
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-users of lipid-lowering medications)
Study: 8656503
Drug: Lamivudine-zidovudine combination
Normalized name: lamivudine / zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine-zidovudine combination therapy (300 mg lamivudine every 12 hours + 200 mg zidovudine every 8 hours for 24 weeks)
Study: 8656503
Drug: Zidovudine monotherapy
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine monotherapy for 24 weeks
Study: 7010528
Drug: Carbenoxolone sodium
Normalized name: carbenoxolone sodium
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone sodium (Biogastrone tablets) 100 mg three times a day for 4 weeks, continued for another 4 weeks if ulcers were not healed
Study: 7010528
Drug: Dummy tablets
Normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy tablets (control group)
Study: 7010528
Drug: Amiloride 5
Normalized name: amiloride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 5 mg three times a day
Study: 25779222
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - three sessions in 3 months
Study: 25098969
Drug: Discontinued medications
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued medications
Study: 19749003
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF-DPI) 400 microg (1 x 400 microg/inhalation; treatment B)
Study: 19749003
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF-DPI) 400 microg (2 x 200 microg/inhalation; treatment A)
Study: 19749003
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two inhalations; treatment C)
Study: 7607973
Drug: Adjuvant therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapies (ECP and doxorubicin/cyclophosphamide)
Study: 3138056
Drug: Prazepham (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazepham (20 mg)
Study: 31377075
Drug: GC3114 (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC3114 (high-dose, quadrivalent influenza vaccine)
Study: 31377075
Drug: Control (standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard-dose quadrivalent influenza vaccine)
Study: 26994300
Drug: Calcitonin gene-related
Normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin gene-related peptide infusion (1.5 µg/min)
Study: 26321502
Drug: Standard-dose epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epirubicin and cyclophosphamide (SDE) (8 × 60 mg/m(2))
Study: 26321502
Drug: Higher-dose epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose epirubicin and cyclophosphamide (HDE) (8 × 100 mg/m(2))
Study: 12117043
Drug: Theophylline (Theo-Dur
Normalized name: THEOPHYLLINE (THEO-DUR) 300MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (Theo-Dur 300 mg bd)
Study: 9570170
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg 3 times a day plus Omeprazole 40 mg daily for 14 days followed by 20 mg daily for 14 days (Group 1)
Study: 9570170
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for 28 days (Group 2)
Study: 9570170
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride 150 mg twice a day for 28 days (Group 3)
Study: 16961011
Drug: Interpretive play
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interpretive play therapy
Study: 30268262
Drug: Kefir group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kefir group (2 × 100 ml of kefir per day)
Study: 30268262
Drug: Toothpaste group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste group (toothpaste with probiotic content, brushed twice a day)
Study: 24473502
Drug: Amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone plus ranolazine (1500 mg single oral dose)
Study: 11281469
Drug: Normal menstrual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal menstrual blood loss (<60 mL)
Study: 9690973
Drug: Sertindole (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (24 mg)
Study: 26957279
Drug: Hemoperfusion combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoperfusion combined therapy (HD+HP)
Study: 26434090
Drug: Anterolateral joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterolateral joint line injection site